Celecoxib

Celebrex capsules are labeled for osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis (JRA) from age 2 years, ankylosing spondylitis, acute pain in adults and primary dysmenorrhea. The current capsule label does not list familial adenomatous polyposis or migraine as approved indications.

The label describes relief of signs/symptoms and pain rather than a universal cure or disease-modifying arthritis regimen. This profile concerns oral capsules; any separately marketed celecoxib formulation requires its own indication and administration instructions.

Individualize treatment and reassess ongoing need. These are the labeled indication-specific oral schedules.

The label provides weight categories below, not a generalized dose for any pediatric pain condition. Children <10 kg, age <2 or with active systemic features were not studied. Systemic-onset JRA requires coagulation vigilance.

Reduce the recommended daily dose by 50% in moderate hepatic impairment (Child-Pugh B); severe hepatic impairment is not recommended. Adults known/suspected to be CYP2C9 poor metabolizers should start at half the lowest recommended dose. For poor-metabolizer JRA patients, consider an alternative treatment. Do not simply halve an already high regimen or infer a combined-adjustment formula.

Labeled regimens can be taken without regard to meal timing. For difficulty swallowing, empty the entire capsule contents onto one level teaspoon of cool or room-temperature applesauce and take immediately with water. The prepared mixture may be refrigerated at 2–8°C for up to 6 hours. Do not estimate partial capsule doses from sprinkled contents.

Severe renal insufficiency is not recommended; advanced renal disease generally requires avoiding use unless expected benefit outweighs risk, with monitoring if used. Correct dehydration/hypovolemia first. Older adults should start at the low end when use is justified; those weighing <50 kg should begin at the lowest recommended dose. The label supplies no fixed eGFR dose-reduction table.

Known celecoxib/component hypersensitivity, prior allergic-type reactions to sulfonamides, asthma/urticaria/other allergic reactions after aspirin or other NSAIDs, and use in the setting of CABG surgery are contraindicated. The label also excludes patients with previous serious skin reactions to NSAIDs. Check the nature of reported allergies rather than dismissing the product’s specific sulfonamide warning.

NSAIDs increase the risk of potentially fatal MI and stroke; risk can begin early and increase with duration. Celecoxib is contraindicated around CABG surgery. GI bleeding, ulceration or perforation can occur at any time without warning and can be fatal; older adults and patients with prior ulcer/GI bleed are especially vulnerable.

Commonly reported effects include dyspepsia, abdominal pain, diarrhea, nausea, flatulence, dizziness, rash and peripheral edema. Serious events include GI bleeding, cardiovascular thrombosis, kidney injury, liver injury, blood-count abnormalities and severe allergy/skin reactions. Trial and postmarketing lists do not establish the same frequency or causality for every reported event.

Warfarin/other anticoagulants, aspirin/other antiplatelets, SSRIs and SNRIs increase bleeding risk; monitor for bleeding. Analgesic-dose aspirin and other NSAIDs/salicylates are not generally recommended together. Low-dose aspirin needs clinician review; celecoxib is not a substitute for its antiplatelet purpose. Corticosteroids also increase GI ulcer/bleeding risk.

Celecoxib can blunt ACE inhibitor, ARB, beta-blocker and diuretic effects. ACE inhibitor/ARB combinations particularly raise renal risk with older age, renal impairment or volume depletion: monitor pressure, hydration and renal function at initiation and periodically. Diuretics require efficacy/renal surveillance; cyclosporine combinations can increase nephrotoxicity.

Monitor for lithium toxicity and relevant levels when used together. Monitor serum digoxin because exposure/half-life may rise. Methotrexate toxicity monitoring remains necessary despite a lack of demonstrated celecoxib effect on methotrexate pharmacokinetics in the label.

CYP2C9 inhibitors such as fluconazole raise celecoxib exposure; inducers such as rifampin may reduce efficacy. Dose adjustment may be warranted. Celecoxib inhibits CYP2D6 and may raise exposure to substrates such as atomoxetine; assess those drugs’ adverse effects and dosing.

Concomitant use can increase myelosuppression, renal and GI toxicity. The celecoxib label specifically calls for close monitoring with CrCl 45–79 mL/min and describes different hold windows for short- and long-half-life NSAIDs. Obtain a drug-specific oncology plan rather than applying an unspecified NSAID hold window to celecoxib independently.

At about 20–30 weeks, use only when clinically necessary at the lowest effective dose for the shortest duration; consider amniotic-fluid ultrasound if treatment exceeds 48 hours and discontinue for oligohydramnios. Avoid at about 30 weeks and later because fetal ductal closure adds to renal/low-fluid risk. Earlier-pregnancy data are inconclusive. NSAIDs may reversibly delay ovulation; consider stopping when conception is difficult or infertility is being assessed.

Small published reports found low milk levels, with limited infant-outcome evidence. The label advises caution and weighing maternal need against breastfeeding benefits and potential infant effects; low exposure does not prove safety for every infant.

JRA use is approved from age 2 with the ≥10 kg dose schedule. Pediatric safety/effectiveness beyond 6 months and long-term cardiovascular risk are not established. Active systemic JRA features were not studied. Systemic-onset JRA needs abnormal coagulation/DIC monitoring; poor CYP2C9 metabolizers may need an alternative.

Child-Pugh B requires a 50% daily-dose reduction; Child-Pugh C and severe renal insufficiency are not recommended. Older adults face greater cardiovascular, GI and renal risk and require cautious selection and monitoring. Lack of a routine age-based adjustment does not remove these risks.

Reduced prostaglandin production supports analgesic, anti-inflammatory and antipyretic effects. Celecoxib does not provide aspirin-like antiplatelet prophylaxis. Prostaglandin suppression also contributes to sodium/water retention and renal risk.

Peak concentration occurs around 3 hours after oral dosing; effective half-life is about 11 hours and steady state is reached by about day 5. Protein binding is about 97%. CYP2C9 forms inactive metabolites, with elimination predominantly after hepatic metabolism through feces and urine; little unchanged drug is recovered.

High-fat food delays the peak and modestly increases exposure; recommended regimens can generally be taken regardless of meals. Moderate hepatic impairment and CYP2C9 poor metabolism can substantially raise exposure. An applesauce mixture of full capsule contents has comparable overall systemic exposure to an intact capsule.

Check pressure at initiation and during treatment; assess edema/heart-failure symptoms and renal risk. Consider periodic CBC and chemistry testing for long-term use; investigate anemia, liver symptoms or renal decline. Monitor interacting drugs as appropriate. In systemic JRA, evaluate abnormal coagulation/bleeding.

Seek emergency help for chest pain, stroke symptoms, breathing difficulty or face/throat swelling. Stop and seek assessment for black stools, vomiting blood, severe abdominal pain, jaundice or a rash/fever suggesting hypersensitivity. Report unexplained weight gain/edema or worsening dyspnea promptly. Read the Medication Guide with each prescription.

Avoid adding another NSAID or aspirin without advice; OTC cold/fever/insomnia products may contain NSAIDs. Suspected excess ingestion needs poison-service/emergency assessment. Treatment is supportive; there is no specific antidote and high protein binding makes dialysis unlikely to help. Do not attempt home vomiting or charcoal dosing.

Current Viatris Celebrex 200 mg capsule is white with a gold band, 7767 on the cap and 200 on the body; 100-count NDC 58151-084-01. The 100 mg capsule uses a blue band, 50 mg red and 400 mg green. Verify the actual package rather than identifying medicine by color alone.

Reviewed Celebrex oral capsules contain 50, 100, 200 or 400 mg celecoxib. A capsule-content applesauce instruction is not authorization to create a partial-dose suspension. Other manufacturers and separately marketed formulations need their own labels.

Store capsules at 20–25°C, with permitted excursions of 15–30°C. For the prescribed full-capsule applesauce mixture, use immediately with water or refrigerate at 2–8°C for no more than 6 hours. Keep medicines safely away from children.